Want to see AU:BIT full AI Analyst Report?
BIT Stock Chart & Stats
<AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EDT
<AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.10
Previous CloseN/A
Volume85.94M
Average Volume (3M)1.60M
Market Cap
AU$6.96M
Enterprise ValueAU$2.86
Total Cash (Recent Filing)AU$1.64M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,785,205,000
10 Day Avg. Volume3,265,462
30 Day Avg. Volume1,601,469
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.63
Price to Sales (P/S)1.10
P/FCF Ratio-3.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtA near-zero debt position materially reduces financial risk and interest burden over the medium term. This gives management flexibility to fund R&D via equity or partnerships rather than servicing debt, lowers insolvency risk during clinical trials, and preserves operational runway.
Rebuilt Equity BaseRecovering from negative equity improves balance-sheet stability and credibility with investors and partners. A repaired capital base supports future fundraising, reduces counterparty concerns, and lessens likelihood of restrictive covenants that could impede long-term R&D programs or strategic collaborations.
Improving Margins And Lower Cash BurnA trend toward smaller losses and materially reduced cash burn signals stronger cost discipline and a longer runway absent immediate financing. Sustained improvement can increase the odds of completing value-creating clinical milestones and attract partners or non-dilutive funding over the coming months.
Bears Say
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow indicate ongoing reliance on external financing to sustain operations. Over a multi-month horizon this raises dilution risk, constrains strategic flexibility, and may force prioritization or delay of development programs if fresh capital is limited.
Small, Volatile RevenueVery small and inconsistent revenue undermines the company’s ability to offset fixed R&D and G&A costs or demonstrate commercial traction. Structural revenue volatility reduces predictability of funding needs and weakens negotiating leverage with partners and licensors over the medium term.
Continued Loss-making ProfitabilityOngoing negative margins mean the business cannot self-fund development and must raise capital until profitable or partnered. In biotech, extended loss periods increase dilution risk and compress potential returns for equity holders if clinical progress or licensing outcomes are delayed.
Biotron News
BIT FAQ
What was Biotron Limited’s price range in the past 12 months?
Biotron Limited lowest share price was AU$0.01 and its highest was AU$0.10 in the past 12 months.
What is Biotron Limited’s market cap?
Biotron Limited’s market cap is AU$6.96M.
When is Biotron Limited’s upcoming earnings report date?
Biotron Limited’s upcoming earnings report date is Mar 04, 2027 which is in 191 days.
How were Biotron Limited’s earnings last quarter?
Currently, no data Available
Is Biotron Limited overvalued?
According to Wall Street analysts Biotron Limited’s price is currently Overvalued.
Does Biotron Limited pay dividends?
Biotron Limited does not currently pay dividends.
What is Biotron Limited’s EPS estimate?
Biotron Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biotron Limited have?
Biotron Limited has 2,785,205,000 shares outstanding.
What happened to Biotron Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biotron Limited?
Currently, no hedge funds are holding shares in AU:BIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biotron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
332.38%
Trailing 12-Months
Company Description
Biotron Limited
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase II clinical evaluations for addressing infections caused by SARS-CoV-2, HIV-1, and the hepatitis C virus. Established in 1999, the company operates from its main office in Sydney, Australia.
Starpharma Holdings Limited
―
Immuron Limited
―
Bio-Gene Technology Ltd.
―
Biome Australia Ltd
―
Recce Pharmaceuticals Ltd.
―